Intellia Therapeutics, Inc. (NTLA)

Market Cap	967.56M
Revenue (ttm)	43.09M
Net Income (ttm)	-522.28M
Shares Out	101.85M
EPS (ttm)	-5.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,318,795
Open	9.49
Previous Close	9.42
Day's Range	9.32 - 9.69
52-Week Range	9.25 - 34.87
Beta	1.83
Analysts	Buy
Price Target	53.00 (+457.9%)
Earnings Date	Feb 20, 2025

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2016
• Employees: 526
• Stock Exchange: NASDAQ
• Ticker Symbol: NTLA
• Website: https://www.intelliatx.com

Financial Performance

In 2023, Intellia Therapeutics's revenue was $36.28 million, a decrease of -30.40% compared to the previous year's $52.12 million. Losses were -$481.19 million, 1.48% more than in 2022.

Analyst Forecast

According to 17 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $53.0, which is an increase of 457.90% from the latest price.

Price Target

$53.0

(457.90% upside)

Analyst Consensus: Buy